JP Morgan initiated coverage of Amyris with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2023 | $3.10 → $0.65 | Buy → Hold | Jefferies |
| 5/10/2023 | $4.00 → $1.25 | Outperform → Market Perform | TD Cowen |
| 4/28/2023 | $1.50 | Buy | Canaccord Genuity |
| 11/10/2022 | Overweight → Neutral | JP Morgan | |
| 11/9/2022 | Outperform → Perform | Oppenheimer | |
| 8/10/2022 | $4.00 → $2.00 | Buy → Neutral | ROTH Capital |
| 6/24/2022 | Neutral | JP Morgan | |
| 5/25/2022 | $2.50 | Neutral | Piper Sandler |
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
S-8 POS - AMYRIS, INC. (0001365916) (Filer)
Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously
TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously
Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
SC 13D/A - AMYRIS, INC. (0001365916) (Subject)
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharm
Gainers PhenomeX Inc. (NASDAQ:CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash transaction for $1 per share. Tivic Health Systems, Inc. (NASDAQ:TIVC) shares jumped 39.1% to $0.0932. Tivic Health Systems shares jumped 80% on Wednesday after the company announced its funded study started enrollment for its non-invasive bioelectronic device approach to vagus nerve stimulation. Sunlight Financial Holdings Inc. (NYSE:SUNL) climbed 36.9% to $0.2101 after declining 8% on Wednesday. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares rose 30.2% to $5.00. Advanced Health Intelligen
Gainers AGBA Group Holding Limited (NASDAQ:AGBA) shares surged 49.4% to $1.31 in pre-market trading after the company reported a 325% year-over-year growth in its second-quarter revenue. AMC Entertainment Hldg Pref Equity Units (NYSE:APE) rose 29.8% to $2.31 in pre-market trading after AMC gained court approval for its revised stock conversion plan. Proterra Inc. (NASDAQ:PTRA) shares gained 25.2% to $0.1483 in pre-market trading on continued volatility after the company announced it filed for Chapter 11 bankruptcy. United States Steel Corporation (NYSE:X) shares rose 23% to $27.95 in pre-market trading. United States Steel late Sunday rejected a buyout offer from rival steel manufactu
EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President
Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th
EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce
EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
3 - AMYRIS, INC. (0001365916) (Issuer)
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.
EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce